Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. , based in the US, focuses on developing and commercializing innovative radioimmunotherapy and antibody-based therapies for the treatment of pediatric oncology and other challenging diseases. Y-mAbs Therapeutics, Inc. specializes in advanced therapies for cancer treatment, with its headquarters located in New York, US.

Founded in 2014, the company has successfully completed 3 deals, with its most recent deal being an IPO in September 2018, raising USD 96 mn by selling 6 million shares at USD 16 each. The current CEO is Claus San Pedro and Michael Rossi. Y-mAbs Therapeutics specializes in the development and commercialization of innovative radioimmunotherapy and antibody-based therapies aimed at treating challenging diseases, particularly in pediatric oncology. The company’s flagship product, DANYELZA® (naxitamab-gqgk), is designed to target high-risk neuroblastoma and has been instrumental in improving treatment outcomes for children suffering from this aggressive cancer.

In addition to DANYELZA®, Y-mAbs has a robust pipeline that focuses on enhancing the efficacy and safety of radioimmunotherapy treatments for both children and adults facing various cancers. The company primarily serves healthcare providers, hospitals, and specialty clinics in North America and Europe, facilitating access to advanced therapeutic solutions that aim to extend and improve patients' lives. Y-mAbs Therapeutics generates revenue through the sale of its proprietary therapies, particularly focusing on DANYELZA®. The company engages in direct transactions with hospitals and healthcare providers, structured on a business-to-business (B2B) model, which involves agreements for supplying its therapeutic products.

In 2024, the company reported a revenue amounting to USD 87. 69 mn, with an EBITDA of USD -30. 67 mn. Y-mAbs Therapeutics plans to leverage its recent funding from the IPO in September 2018, which raised USD 96 mn, to support the development of new innovative products targeting various cancers.

The company aims to expand its market presence into Europe and Asia by 2025, enhancing its reach in pediatric oncology therapies and potentially launching new treatments within the next two years.